Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

Abstract

We performed a pilot trial in refractory cancer patients to investigate the feasibility of intratumoral injection of TAPET-CD, an attenuated Salmonella bacterium expressing the E. coli cytosine deaminase gene. A total of three patients received three dose levels of TAPET-CD (3 × 106–3 × 107 CFU/m2) via intratumoral injection once every 28 days as long as progression of disease or intolerable toxicity was not observed. From days 4 to 14 of each 28 day cycle, patients also received 5-fluorocytosine (5-FC) at a dose of 100 mg/kg/day p.o. divided three times daily. Six cycles of treatment were administered. No significant adverse events clearly attributable to TAPET-CD were demonstrated. Two patients had intratumor evidence of bacterial colonization with TAPET-CD, which persisted for at least 15 days after initial injection. Conversion of 5-FC to 5-fluorouracil (5-FU) as a result of cytosine deaminase expression was demonstrated in these two patients. The tumor to plasma ratio of 5-FU for these two colonized patients was 3.0, demonstrating significantly increased levels of 5-FU at the site of TAPET-CD colonization and insignificant systemic spread of the bacteria. In contrast, the tumor to plasma ratio of 5-FU of the patient who did not show colonization of TAPET-CD was less than 1.0. These results support the principle that a Salmonella bacterium can be utilized as a delivery vehicle of the cytosine deaminase gene to malignant tissue and that the delivered gene is functional (i.e. able to convert 5-FC to 5-FU) at doses at or below 3 × 107 CFU/m2.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Mose JR, Mose G . Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich Tumor des Maus. Z Krebsforsch. 1959;63:63–74.

    Article  Google Scholar 

  2. Mose JR, Mose G . Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 1964;24:212–216.

    Google Scholar 

  3. Thiele EH, Arison R, Boxer GE . Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res. 1964;2:222–233.

    Google Scholar 

  4. Engelbart K, Gericke D . Oncolysis by clostridia V. Transplanted tumors of the hamster. Cancer Res. 1954;24:239–243.

    Google Scholar 

  5. Carey RW, Holland JF, Whang HY, et al. Clostridial oncolysis in man. Eur J Cancer. 1967;3:37–46.

    Article  Google Scholar 

  6. Heppner F, Mose J . The liquefaction (oncolysis) of malignant gliomas by a non-pathogenic clostridium. Acta Neurol. 1978;12:123–125.

    Google Scholar 

  7. Heppner F, Mose J, Ascher PW, Walter G . Oncolysis of malignant gliomas of the brain. The 13th International Congress on Chemotherapy, 1983: vol 226, 38–45.

  8. Giel CP . Abscess formation in pheochromocytoma. N Engl J Med. 1954;251:980–982.

    Article  CAS  Google Scholar 

  9. Simmers TA, Mijnhout G, Van Meyel JJ . Salmonellosis: an usual complication of hepatocellular carcinoma. Scand J Gastroenterol. 1997;32:1180–1182.

    Article  CAS  Google Scholar 

  10. Noguerado A, Cabanyes J, Vivancos J, et al. Abscess caused by Salmonella enteritidis within a glioblastoma multiforme. J Infect. 1987;15:61–63.

    Article  CAS  Google Scholar 

  11. Black PH, Kunz LJ, Swartz MN . Salmonellosis: a review of some unusual aspects. N Engl J Med. 1960;262:921–926.

    Article  CAS  Google Scholar 

  12. Rodriguez RE, Valero V, Watanakunakom C . Salmonella focal intracranial infections: review of the world literature (1884–1984) and report of an usual case. Rev Infect Dis. 1986;8:31–41.

    Article  CAS  Google Scholar 

  13. Grahm FO, Coleman PN . Infection of a secondary carcinoma by Salmonella montevideo. BMJ. 1952;1:1116.

    Article  Google Scholar 

  14. Luo X, Ittensohn M, Liu Y, et al. Genetically modified Salmonella typhimurium inhibited growth of primary tumors and metastases. Proc Am Assoc Cancer Res. 1999;40:87.

    Google Scholar 

  15. Low K, Ittensohn M, Lin S, et al. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors. Proc Am Assoc Cancer Res. 1999;40:87.

    Google Scholar 

  16. Low KB, Ittensohn M, Le T, et al. Lipid A mutant salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17:37–41.

    Article  CAS  Google Scholar 

  17. Pawelek JM, Low KB, Bermudes D . Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537–4544.

    CAS  PubMed  Google Scholar 

  18. Khan SA, Everest P, Servos S . A lethal role for lipid A in salmonella infection. Mol Microbiol. 1998;29:571–579.

    Article  CAS  Google Scholar 

  19. Lee KC, Zheng LM, Margitich D, Almassian B, King I . Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain. TAPET-CD, being developed as an anti-tumor agent. Int J Toxicol. 2001;20:207–217.

    Article  CAS  Google Scholar 

  20. Zheng LM, Luo X, Feng M, et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res. 2000;12:127–135.

    Article  CAS  Google Scholar 

  21. Luo X, Li Z, Lin S, et al. Anti-tumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res. 2002;12:501–508.

    Article  Google Scholar 

  22. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20:142–152.

    Article  Google Scholar 

  23. Dinarello CA . Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112:321S–329S.

    Article  CAS  Google Scholar 

  24. King I, Bermudes D, Lin S, et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther. 2002;13:1225–1233.

    Article  CAS  Google Scholar 

  25. Deonarain MP, Spooner RA, Epenetos AA . Genetic delivery of enzymes for cancer therapy. Gene Therapy. 1995;2:235–244.

    CAS  PubMed  Google Scholar 

  26. Haskell CM, Fluorouracil. In: In Cancer Treatment. WB Sounds Company. 1995: 116–119.

  27. Austin EA, Huber BE . A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 1993;43:380–387.

    CAS  PubMed  Google Scholar 

  28. Liu SC, Minton NP, Giaccia AJ, Brown JM . Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy. 2002;9:291–296.

    Article  CAS  Google Scholar 

  29. Donnenburg MS, Kaper JB . Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immunity. 1991;59:4310–4317.

    Google Scholar 

  30. Platt J, Sodi S, Kelly M, et al. Antitumor effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer. 2000;36:2397–2402.

    Article  CAS  Google Scholar 

  31. Khil MS, Kim JH, Mullen CA, et al. Radiosensitization of 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996;2:53–57.

    CAS  PubMed  Google Scholar 

  32. Gabel M, Kim JH, Kolozsvary A, et al. Selective in vivo radiosensitization by 5-fluorouracil of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase gene. Int J Radiat Oncol Biol Phys. 1998;41:883–887.

    Article  CAS  Google Scholar 

  33. Lawrence TS, Rehemtulla A, Ng EY . Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res. 1998;58:2588–2593.

    CAS  PubMed  Google Scholar 

  34. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves and efficient memory. J Immunol. 1995;154:5302–5312.

    CAS  PubMed  Google Scholar 

  35. Pierrefite-Carle V, Baque P, Gavelli A, et al. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst. 1999;91:2014–2019.

    Article  CAS  Google Scholar 

  36. Hermiston T . Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses. Curr Opin Mol Ther. 2002;4:334–342.

    CAS  PubMed  Google Scholar 

  37. Galanis E, Vile R, Russell SJ . Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001;38:177–192.

    Article  CAS  Google Scholar 

  38. Greco O, Dachs GU . Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 2001;187:22–36.

    Article  CAS  Google Scholar 

  39. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997;8:985–1001.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge Brenda Marr and Elizabeth Asilo for their competent and knowledgeable assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Nemunaitis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nemunaitis, J., Cunningham, C., Senzer, N. et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10, 737–744 (2003). https://doi.org/10.1038/sj.cgt.7700634

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700634

Keywords

This article is cited by

Search

Quick links